Exicure Inc. (XCUR)
NASDAQ: XCUR
· Real-Time Price · USD
6.65
-0.20 (-2.92%)
At close: Aug 15, 2025, 3:59 PM
7.12
7.07%
After-hours: Aug 15, 2025, 05:38 PM EDT
Company Description
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology.
Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.
The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.
Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure Inc.
| Country | United States |
| IPO Date | May 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Andy Yoo |
Contact Details
Address: 2430 North Halsted Street Chicago, Illinois United States | |
| Website | https://www.exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M3097 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andy Yoo | Chief Executive Officer, President & Director |
| Seung Ik Baik | Chief Financial Officer, Secretary & Director |
| Joshua Miller | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 08, 2025 | 10-Q | Quarterly Report |
| Aug 08, 2025 | 8-K | Current Report |
| Aug 04, 2025 | 8-K | Current Report |
| Jul 11, 2025 | S-1 | Filing |
| Jun 27, 2025 | 10-Q | Quarterly Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 10, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 23, 2025 | 4 | Filing |
| May 15, 2025 | NT 10-Q | Filing |